AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - AbCellera Biologics Inc. reported a revenue of $9.18 million for the quarter ended December 2023, reflecting a year-over-year decline of 57.4% [1] - The company's EPS for the same period was -$0.17, compared to -$0.10 a year ago [1] - The reported revenue fell short of the Zacks Consensus Estimate of $9.58 million, resulting in a surprise of -4.19% [1] - The EPS also missed the consensus estimate of -$0.14, with a surprise of -21.43% [1] Revenue Breakdown - Research fees generated $8.74 million, exceeding the estimated $8.34 million, but representing a year-over-year decline of 23.5% [2] - Licensing revenue was $0.19 million, below the estimated $0.32 million, but showed a year-over-year increase of 12.1% [2] - Milestone payments totaled $0.25 million, significantly lower than the estimated $1.16 million, marking a 50% decline year-over-year [2] Stock Performance - Over the past month, shares of AbCellera Biologics Inc. have returned -3.1%, contrasting with the Zacks S&P 500 composite's increase of +3.6% [2] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [2]